Rekombinanter VEGF (Ranibizumab Biosimilar) Antikörper

Produktnummer ABIN7200657

Der Maus Monoklonal Anti-VEGF (Ranibizumab Biosimilar)-Antikörper wurde für FACS und in vivo validiert. Er ist geeignet, VEGF (Ranibizumab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter VEGF (Ranibizumab Biosimilar) Antikörper (ABIN7200657)

Target: VEGF (Ranibizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Fragment: Fab fragment

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser VEGF (Ranibizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Produktdetails anti-VEGF (Ranibizumab Biosimilar) Antikörper

Verwendungszweck: Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)

Spezifität: The Fab protein ranibizumab specifically binds to the human VEGF-A.

Produktmerkmale: Recombinant Humanized Monoclonal Antibody Fragment (Fab) generated from the same parent mouse antibody as bevacizumab.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.

Anwendungsinformationen

Applikationshinweise: Functional assay, neutralization.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu VEGF (Ranibizumab Biosimilar)

Target: VEGF (Ranibizumab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.